ScreenerHero

ACTU Actuate Therapeutics, Inc. Common stock

NAS · US · Healthcare · Biotechnology · actuatetherapeutics.com
0.8116USD-7.24%Mkt Cap: 19.49M $P/E: —

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synth…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap19.49M USD
Enterprise Value15.24M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.23M USD
Revenue/Share—
Last Price0.8116 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.23
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B19.98
EPS (TTM)-0.87
EPS (Forward)-0.66
52W Range
0.60423% of range8.490
52W High8.490 USD
52W Low0.6042 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-280.51%
ROA-158.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.21M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-64.02%
Net Debt-4.43M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.25
Quick Ratio1.16
Book Value/Sh0.04 USD
Cash/Share0.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)11.68 USD
Upside (mean)+1339.5%
Target Range8.000 USD – 15.05 USD
8.000+1339.5% to mean15.05
# Analysts3
Ownership
Shares Out.24.01M
Float8.60M
Insiders15.41%
Institutions56.29%
Short Interest
Short Ratio2.3d
Short % Float10.39%
Short % Out.4.57%
Shares Short1.10M
Short (prev mo.)695.97K
Technical
SMA 501.112 (-27.0%)
SMA 2002.736 (-70.3%)
Beta0.96
S&P 52W Chg14.58%
Avg Vol (30d)368.28K
Avg Vol (10d)272.25K
Technical Indicators
RSI (14)42.7
MACD-0.1146
MACD Signal-0.1242
MACD Hist.+0.0095
BB Upper1.404 USD
BB Middle0.9334 USD
BB Lower0.4627 USD
BB Width100.86%
ATR (14)0.1528 USD
Vol Ratio (20d)0.76x